Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
10
06
2019
accepted:
20
10
2019
entrez:
7
2
2020
pubmed:
7
2
2020
medline:
7
2
2020
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer deaths worldwide. The high mortality rate in HCC is largely due to the difficulty of early detection. In this study, to improve patient outcomes, serum samples from 345 patients with HCC, 46 patients with chronic hepatitis (CH), 93 patients with liver cirrhosis (LC), and 1,033 healthy individuals were analyzed with microRNA (miRNA) microarrays. We investigated the diagnostic potential of circulating miRNAs in serum and developed a detection model of HCC, including early stage. A diagnostic model was constructed based on the expression levels of a combination of miRNAs in a discovery set. We selected 52 miRNAs that had altered expressions according to disease progression status, established the diagnostic model with a combination of eight miRNAs in the discovery set, and tested the model in a validation set. The diagnostic values for discriminating cancer from HCC at-risk control samples were as follows: area under the curve, 0.99; sensitivity, 97.7%; specificity, 94.7%. With this model, 98% of stage I HCC cases were detected; these results were much better than those observed from conventional methods.
Identifiants
pubmed: 32025611
doi: 10.1002/hep4.1451
pii: HEP41451
pmc: PMC6996324
doi:
Types de publication
Journal Article
Langues
eng
Pagination
284-297Informations de copyright
© 2019 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
Références
Biomed Pharmacother. 2016 Jul;81:431-438
pubmed: 27261623
J Clin Oncol. 2011 Dec 20;29(36):4781-8
pubmed: 22105822
PLoS Med. 2014 Apr 01;11(4):e1001624
pubmed: 24691105
J Mol Diagn. 2013 Nov;15(6):827-34
pubmed: 23988620
Cancer Sci. 2016 Mar;107(3):326-34
pubmed: 26749252
J Hepatol. 2012 Jan;56(1):167-75
pubmed: 21749846
Nat Commun. 2018 Oct 17;9(1):4319
pubmed: 30333487
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
J Clin Invest. 2016 Apr 1;126(4):1163-72
pubmed: 26974161
BMC Cancer. 2015 Oct 20;15:748
pubmed: 26487644
Nucleic Acids Res. 2017 Sep 19;45(16):9290-9301
pubmed: 28934507
Hepatology. 2003 May;37(5):1114-21
pubmed: 12717392
Nucleic Acids Res. 2014 Jan;42(Database issue):D68-73
pubmed: 24275495
Lancet Oncol. 2015 Jul;16(7):804-15
pubmed: 26088272
Biomarkers. 2009 Nov;14(7):529-38
pubmed: 19863192
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
PLoS One. 2017 Nov 15;12(11):e0187638
pubmed: 29141042
Oncotarget. 2017 Dec 30;9(12):10402-10416
pubmed: 29535815
Oncotarget. 2017 Sep 6;8(52):89811-89823
pubmed: 29163790
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Biol Psychiatry. 2011 Jan 15;69(2):188-93
pubmed: 21183010
Aliment Pharmacol Ther. 2017 Jan;45(1):169-177
pubmed: 27862091
World J Gastroenterol. 2015 Apr 7;21(13):3928-35
pubmed: 25852278
Hepatology. 1994 Jan;19(1):61-6
pubmed: 7506227
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Clin Cancer Res. 2017 Sep 1;23(17):5311-5319
pubmed: 28606918
Gastroenterology. 2013 Dec;145(6):1300-11
pubmed: 23933602
Int J Clin Oncol. 2017 Jun;22(3):413-420
pubmed: 28243946
PLoS One. 2009;4(5):e5540
pubmed: 19436744
Oncotarget. 2017 Mar 8;8(46):81235-81249
pubmed: 29113383
Oncotarget. 2018 Feb 27;9(20):15350-15364
pubmed: 29632649
Cancer Sci. 2019 Jan;110(1):408-419
pubmed: 30382619
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Cancer Res. 2010 Dec 1;70(23):9798-807
pubmed: 21098710